Journal: Cell Reports Medicine

Article Title: De novo GTP synthesis is a metabolic vulnerability for the interception of brain metastases

doi: 10.1016/j.xcrm.2024.101755

Figure Lengend Snippet:

Article Snippet: APC-conjugated anti-human TRA-1-85 (CD147) , Miltenyi Biotec , Cat#130-128-900; RRID:AB_2921968.

Techniques: Virus, Recombinant, Staining, Labeling, Electron Microscopy, Bradford Assay, RNA Sequencing, Gene Expression, Knock-Out, CRISPR, Luciferase, Software, Fluorescence

Journal: Oncotarget

Article Title: Tumour-associated circulating microparticles: A novel liquid biopsy tool for screening and therapy monitoring of colorectal carcinoma and other epithelial neoplasia

doi: 10.18632/oncotarget.9018

Figure Lengend Snippet: Measured EpCAM + taMP and EpCAM + CD147 + taM P values were set in dependence (Spearman algorithm) to associate patient tumour volumes of indicated cancer entities; ( A–B ): NSCLC; ( C–F ): CRC. Correlations were restricted to 100 cm 3 of tumour volume. (D/F) Detail analysis of indicated tumour ranges revealing the possible lower and upper detection limit. Shown are indicated median with 25 and 95 percentile including p -value as indicated; * = p < 0.05, ** = p < 0.005, *** = p < 0.0005, n.s. = not significant (one-way ANOVA test including multiple comparisons using Dunn's Multiple Comparison Test). Overall, an error level p < 0.05 was considered significant. Calculations were done with Prism 5 (GraphPad Software, Inc., USA).

Article Snippet: MPs sedimenting at 20,000 g were characterized by FACS using staining for AnnexinV, CD147, EpCAM (eBioscienceTM, San Diego, CA; BioLegend; Miltenyi Biotec, Bergisch Gladbach, Germany, respectively).

Techniques: Comparison, Software

Journal: Oncotarget

Article Title: Tumour-associated circulating microparticles: A novel liquid biopsy tool for screening and therapy monitoring of colorectal carcinoma and other epithelial neoplasia

doi: 10.18632/oncotarget.9018

Figure Lengend Snippet: ( A–B ) Measured EpCAM + taMP and EpCAM + CD147 + taMP values were set in dependence (Spearman algorithm) to associate patient UICC values. ( C–D ) Direct comparison of indicated taMPs population in metastatic CRC (mCRC) vs. non-metastatic CRC and healthy controls. (E/F) Direct comparison of measured CEA and CA 19–9 values in ng/mL in metastatic CRC (mCRC) vs. non-metastatic CRC. Shown are indicated median with 25 and 95 percentile including p -value as indicated; * = p < 0.05, ** = p < 0.005, *** = p < 0.0005, n.s. = not significant (one-way ANOVA test including multiple comparisons using Dunn's Multiple Comparison Test (C/D) or unpaired Mann-Whitney test (E/F)).

Article Snippet: MPs sedimenting at 20,000 g were characterized by FACS using staining for AnnexinV, CD147, EpCAM (eBioscienceTM, San Diego, CA; BioLegend; Miltenyi Biotec, Bergisch Gladbach, Germany, respectively).

Techniques: Comparison, MANN-WHITNEY

Journal: Oncotarget

Article Title: Tumour-associated circulating microparticles: A novel liquid biopsy tool for screening and therapy monitoring of colorectal carcinoma and other epithelial neoplasia

doi: 10.18632/oncotarget.9018

Figure Lengend Snippet: ( A ) EpCAM + taMPs levels 7 days post CRC tumour resection and at day 10 post-OP. ( B ) Paired display of accompanied post-OP and post-OP values of indicated taMP populations. ( C ) EpCAM + CD147 + taMPs levels 7 days post CRC tumour resection and at day 10 post-OP. ( D ) CD147 + EpCAM − taMPs levels 7 days post CRC tumour resection and at day 10 post-OP. Shown are indicated median with 25 and 95 percentile including p -value as indicated; * = p < 0.05, ** = p < 0.005, *** = p < 0.0005, n.s. = not significant (paired t -test with Wilcoxon matched pairs signed rank-test). Overall, an error level p < 0.05 was considered significant. ( E ) Sketch illustrating the heterogeneous tumour composition and tumour antigens used in the current study. Tumour cells shed multiple MP subpopulations carrying a distinguishing set of surface markers. These shedded taMPs can be detected in the sera of cancer patients.

Article Snippet: MPs sedimenting at 20,000 g were characterized by FACS using staining for AnnexinV, CD147, EpCAM (eBioscienceTM, San Diego, CA; BioLegend; Miltenyi Biotec, Bergisch Gladbach, Germany, respectively).

Techniques:

Journal: Stem cell research

Article Title: Establishment of a human embryonic stem cell line with homozygous TP53 R248W mutant by TALEN mediated gene editing

doi: 10.1016/j.scr.2018.04.013

Figure Lengend Snippet: Reagents details.

Article Snippet: Pluripotency Markers , Mouse anti-TRA-1-85 Alexa Fluor 555-conjugated , 1:600 , R and D Systems Cat# FAB3195A RRID:AB_663789.

Techniques: Immunocytochemistry, Western Blot, Mutagenesis

Journal: Stem cell research

Article Title: Generation of six human induced pluripotent stem cell sublines (MZT01E, MZT01F, MZT01N and MZT02D, MZT02G and MZT02H) for reproductive science research

doi: 10.1016/j.scr.2021.102204

Figure Lengend Snippet: All hiPSC sublines display equivalent features of self-renewal and pluripotency.

Article Snippet: Fibroblasts were passaged using 0.05% Tryspin (Gibco) and re-plated, the derived cells were termed MZT01 and MZT02 based on the order the biopsy was received ( and ). table ft1 table-wrap mode="anchored" t5 caption a7 Classification Test Result Data Morphology Immunofluorescence Normal panel C Phenotype Immunofluorescence Positive for self-renewal markers: Oct4, Nanog, SSEA-4, Tra-1–81 panel C Flow cytometry MZT04-D: panel B Tra 1–81: 85.9%, SSEA-4: 98.7% MZT04-J: Tra 1–81: 92.7%, SSEA-4: 81.5% MZT04-C: Tra 1–81: 84.3%, SSEA-4: 81.5% Genotype Karyotype (G-banding) and resolution 46,XX panel A Identity Microsatellite PCR (mPCR) OR STR analysis Performed Supplementary Fig. 2 16 sites tested, all three lines match each other, and the HDF line they were derived from Supplementary Fig. 2 Mutation analysis (IF APPLICABLE) Sequencing N/A Southern Blot OR WGS N/A Microbiology and virology Mycoplasma Mycoplasma testing by Luminescence Supplementary Fig. 1 Differentiation potential Pluritest Pluripotent panel E Donor screening (OPTIONAL) N/A Genotype additional info (OPTIONAL) N/A N/A Open in a separate window Characterization and validation. table ft1 table-wrap mode="anchored" t5 caption a7 Antibodies used for immunocytochemistry/flow-citometry Antibody Dilution Company Cat # and RRID Self-renewal markers goat-anti-human Oct4 1:100 Santa Cruz, sc8628 RRID: AB_653551 Self-renewal markers goat-anti-human NANOG 1:40 R&D Systems, AF1997 RRID: AB 355097 Self-renewal markers mouse-anti-human SSEA-4 1:100 Developmental Studies Hybridoma Bank, MC-813–70 RRID: AB_528477 Self-renewal markers mouse-anti-human TRA-1–81 1:100 eBiosciences, 14–8883–82 RRID: AB_891614 Pluripotency markers SSEA-4-Allophycocyanin 1:30 R&D Systems, FAB1435A RRID: AB_494994 Pluripotency markers TRA-1–85-Phycoerythrin 1:60 R&D Systems, FAB3195P RRID: AB_2066683 Pluripotency markers TRA-1–81, Alexa Fluor 488 1:60 Stemcell Technologies, 60065AD RRID: AB_2721032 Pluripotency markers Dapi 1:100 BioVision, B1098–25 RRID: AB_2336790 Secondary antibodies AF488-conjugated donkey-anti-goat 1:200 JacksonImmunoResearch, 705–546–147 RRID: AB_2340430 Secondary antibodies AF488-conjugated donkey-anti-mouse 1:200 Life Technologies, A-21131 RRID: AB_2535771 Primers Target Forward/Reverse primer (5′–3′) Reprogramming virus SeV GGA TCA CTA GGT GAT ATC GAG C/ ACC AGA CAA GAG TTT AAG AGA TAT GTA TC Reprogramming virus: KOS ATG CAC CGC TAC GAC GTG AGC GC/ ACC TTG ACA ATC CTG ATG TGG Reprogramming virus: Klf4 TTC CTG CAT GCC AGA GGA GCC C/ AAT GTA TCG AAG GTG CTC AA Reprogramming virus: c-Myc TAA CTG ACT AGC AGG CTT GTC G/ TCC ACA TAC AGT CCT GGA TGA TGA TG Open in a separate window Reagents details.

Techniques:

Journal: Stem cell research

Article Title: Generation of six human induced pluripotent stem cell sublines (MZT01E, MZT01F, MZT01N and MZT02D, MZT02G and MZT02H) for reproductive science research

doi: 10.1016/j.scr.2021.102204

Figure Lengend Snippet: Reagents details.

Article Snippet: Fibroblasts were passaged using 0.05% Tryspin (Gibco) and re-plated, the derived cells were termed MZT01 and MZT02 based on the order the biopsy was received ( and ). table ft1 table-wrap mode="anchored" t5 caption a7 Classification Test Result Data Morphology Immunofluorescence Normal panel C Phenotype Immunofluorescence Positive for self-renewal markers: Oct4, Nanog, SSEA-4, Tra-1–81 panel C Flow cytometry MZT04-D: panel B Tra 1–81: 85.9%, SSEA-4: 98.7% MZT04-J: Tra 1–81: 92.7%, SSEA-4: 81.5% MZT04-C: Tra 1–81: 84.3%, SSEA-4: 81.5% Genotype Karyotype (G-banding) and resolution 46,XX panel A Identity Microsatellite PCR (mPCR) OR STR analysis Performed Supplementary Fig. 2 16 sites tested, all three lines match each other, and the HDF line they were derived from Supplementary Fig. 2 Mutation analysis (IF APPLICABLE) Sequencing N/A Southern Blot OR WGS N/A Microbiology and virology Mycoplasma Mycoplasma testing by Luminescence Supplementary Fig. 1 Differentiation potential Pluritest Pluripotent panel E Donor screening (OPTIONAL) N/A Genotype additional info (OPTIONAL) N/A N/A Open in a separate window Characterization and validation. table ft1 table-wrap mode="anchored" t5 caption a7 Antibodies used for immunocytochemistry/flow-citometry Antibody Dilution Company Cat # and RRID Self-renewal markers goat-anti-human Oct4 1:100 Santa Cruz, sc8628 RRID: AB_653551 Self-renewal markers goat-anti-human NANOG 1:40 R&D Systems, AF1997 RRID: AB 355097 Self-renewal markers mouse-anti-human SSEA-4 1:100 Developmental Studies Hybridoma Bank, MC-813–70 RRID: AB_528477 Self-renewal markers mouse-anti-human TRA-1–81 1:100 eBiosciences, 14–8883–82 RRID: AB_891614 Pluripotency markers SSEA-4-Allophycocyanin 1:30 R&D Systems, FAB1435A RRID: AB_494994 Pluripotency markers TRA-1–85-Phycoerythrin 1:60 R&D Systems, FAB3195P RRID: AB_2066683 Pluripotency markers TRA-1–81, Alexa Fluor 488 1:60 Stemcell Technologies, 60065AD RRID: AB_2721032 Pluripotency markers Dapi 1:100 BioVision, B1098–25 RRID: AB_2336790 Secondary antibodies AF488-conjugated donkey-anti-goat 1:200 JacksonImmunoResearch, 705–546–147 RRID: AB_2340430 Secondary antibodies AF488-conjugated donkey-anti-mouse 1:200 Life Technologies, A-21131 RRID: AB_2535771 Primers Target Forward/Reverse primer (5′–3′) Reprogramming virus SeV GGA TCA CTA GGT GAT ATC GAG C/ ACC AGA CAA GAG TTT AAG AGA TAT GTA TC Reprogramming virus: KOS ATG CAC CGC TAC GAC GTG AGC GC/ ACC TTG ACA ATC CTG ATG TGG Reprogramming virus: Klf4 TTC CTG CAT GCC AGA GGA GCC C/ AAT GTA TCG AAG GTG CTC AA Reprogramming virus: c-Myc TAA CTG ACT AGC AGG CTT GTC G/ TCC ACA TAC AGT CCT GGA TGA TGA TG Open in a separate window Reagents details.

Techniques: Immunocytochemistry, Virus